Pembrolizumab in Combination with Stereotactic Body Radiation Therapy for Liver Metastatic Colorectal Cancer

The PI of this project was: Dustin Deming, MD

This project was funded by: Industry - Merck

The term of this project was: December 2016 to May 2018

The number of subjects scanned during this project was: 15

This is a phase 1b feasibility study to evaluate the use of PD-1 blockade in combination with ablative radiotherapy for the treatment of metastatic colorectal cancer (CRC). This study will examine the sequential combination of stereotactic body radiotherapy (SBRT) and pembrolizumab for patients for whom the goal is eradicating all known sites of disease. It is very likely that for many patients the SBRT therapy will be completed following other modalities including operative resection or ablation.

https://clinicaltrials.gov/ct2/show/NCT02837263